PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Lutter, J. ; Jörres, R.A.* ; Trudzinski, F.C.* ; Alter, P.* ; Kellerer, C.* ; Watz, H.* ; Welte, T.* ; Bals, R.* ; Kauffmann-Guerrero, D. ; Behr, J.* ; Holle, R.* ; F Vogelmeier, C.* ; Kahnert, K.*

Treatment of COPD Groups GOLD A and B with inhaled corticosteroids in the COSYCONET cohort - determinants and consequences.

Int. J. Chron. Obstruct. Pulmon. Dis. 16, 987-998 (2021)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Background: In COPD patients of GOLD groups A and B, a high degree of treatment with inhaled corticosteroids (ICS) has been reported, which is regarded as overtreatment according to GOLD recommendations. We investigated which factors predict ICS use and which relationship it has to clinical and functional outcomes, or healthcare costs. Methods: We used pooled data from visits 1 and 3 of the COSYCONET cohort (n=2741, n=2053, interval 1.5 years) including patients categorized as GOLD grades 1-4 and GOLD group A or B at both visits (n=1080). Comparisons were performed using ANOVA, and regression analyses using propensity matching and inverse probability weighting to adjust for differences between ICS groups. These were defined as having ICS at both visits (always) vs no ICS at both visits (never). Measures were divided into predictors of ICS treatment and outcomes. Results: Among 1080 patients, 608 patients were eligible for ICS groups (n=297 never, n=311 always). Prior to matching, patients with ICS showed significantly (p<0.05 each) impaired lung function, symptoms and exacerbation history. After matching, the outcomes generic quality of life and CO diffusing capacity were increased in ICS patients (p<0.05 each). Moreover, costs for respiratory medication, but not total health care costs, were significantly elevated in the ICS group by 780€ per year. Conclusion: ICS therapy in COPD GOLD A/B patients can have small positive and negative effects on clinical outcomes and health care costs, indicating that the clinical evaluation of ICS over-therapy in COPD requires a multi-dimensional approach.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
3.355
1.270
2
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Copd ; Gold Groups ; Inhaled Corticosteroids ; Overtreatment
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 1176-9106
e-ISSN 1178-2005
Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease
Quellenangaben Band: 16, Heft: , Seiten: 987-998 Artikelnummer: , Supplement: ,
Verlag Dove Medical Press
Verlagsort Albany, Auckland
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Health Economics and Health Care Management (IGM)
Institute of Lung Health and Immunity (LHI)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Genetics and Epidemiology
Lung Research
PSP-Element(e) G-505300-001
G-501600-001
Förderungen Pfizer Pharma GmbH
German Center for Lung Research (DZL)
BMBF
AstraZeneca GmbH
Bayer Schering Pharma AG
Boehringer Ingelheim Pharma GmbH Co. KG
Chiesi GmbH
GlaxoSmithKline
Grifols Deutschland GmbH
MSD Sharp Dohme GmbH
Mundipharma GmbH
Novartis Deutschland GmbH
Takeda Pharma Vertrieb GmbH Co. KG
Teva GmbH
German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET)
DOI 10.2147/COPD.S304532
WOS ID WOS:000640018200001
Scopus ID 85104841049
PubMed ID 33883892
Erfassungsdatum 2021-06-10
[➜Korrektur melden]